The FDA on September 30, 2015 granted accelerated approval to OPDIVO® in combination with YERVOY® (Ipilimumab), for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma. OPDIVO® Injection is a product of Bristol-Myers Squibb Company.
Other Pages – Bottom Ad
Advertisement
Subscribe
